TW202315887A - 抗pla2g2d構築體及其用途 - Google Patents

抗pla2g2d構築體及其用途 Download PDF

Info

Publication number
TW202315887A
TW202315887A TW111129405A TW111129405A TW202315887A TW 202315887 A TW202315887 A TW 202315887A TW 111129405 A TW111129405 A TW 111129405A TW 111129405 A TW111129405 A TW 111129405A TW 202315887 A TW202315887 A TW 202315887A
Authority
TW
Taiwan
Prior art keywords
amino acid
seq
acid sequence
cdr1
cdr2
Prior art date
Application number
TW111129405A
Other languages
English (en)
Chinese (zh)
Inventor
麗芬 李
冠瑜 盧
敏元 柳
詩茜 黃
瑪德琳 吳
愛瑞兒 玉欣 陳
Original Assignee
美商尖端免疫生醫公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商尖端免疫生醫公司 filed Critical 美商尖端免疫生醫公司
Publication of TW202315887A publication Critical patent/TW202315887A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01004—Phospholipase A2 (3.1.1.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW111129405A 2021-08-04 2022-08-04 抗pla2g2d構築體及其用途 TW202315887A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163229437P 2021-08-04 2021-08-04
US63/229,437 2021-08-04

Publications (1)

Publication Number Publication Date
TW202315887A true TW202315887A (zh) 2023-04-16

Family

ID=85156313

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111129405A TW202315887A (zh) 2021-08-04 2022-08-04 抗pla2g2d構築體及其用途

Country Status (8)

Country Link
US (1) US20240327540A1 (enExample)
EP (1) EP4380690A4 (enExample)
JP (1) JP2024528987A (enExample)
CN (1) CN118139894A (enExample)
AU (1) AU2022323177A1 (enExample)
CA (1) CA3178008A1 (enExample)
TW (1) TW202315887A (enExample)
WO (1) WO2023015225A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7814054B2 (ja) * 2020-01-30 2026-02-16 エーペックスイミューン セラピューティクス インコーポレイテッド Ｐｌａ２ｇ２ｄアンタゴニストによる癌またはウイルス感染を処置するための方法および組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1451600A (en) * 1998-10-27 2000-05-15 Incyte Pharmaceuticals, Inc. Human phospholipases
JP7814054B2 (ja) * 2020-01-30 2026-02-16 エーペックスイミューン セラピューティクス インコーポレイテッド Ｐｌａ２ｇ２ｄアンタゴニストによる癌またはウイルス感染を処置するための方法および組成物

Also Published As

Publication number Publication date
CN118139894A (zh) 2024-06-04
EP4380690A1 (en) 2024-06-12
EP4380690A4 (en) 2025-02-26
WO2023015225A1 (en) 2023-02-09
CA3178008A1 (en) 2023-02-04
AU2022323177A1 (en) 2024-03-07
JP2024528987A (ja) 2024-08-01
US20240327540A1 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
US20230067770A1 (en) Anti-cd137 constructs, multispecific antibody and uses thereof
TWI917387B (zh) 抗ｃｄ９３之構築體及其用途
JP7818570B2 (ja) 抗ｃｄ９３構築物およびその使用
JP2023543031A (ja) 抗ｃｄ９３構築物およびその使用
US20230112085A1 (en) Anti-b7-h4 constructs and uses thereof
US20240279334A1 (en) Anti-cd3 constructs and uses thereof
WO2016079050A1 (en) Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
US20220403040A1 (en) Anti-cd137 constructs, multispecific antibody and uses thereof
US20240076395A1 (en) Anti-cd137 constructs and uses thereof
US20240327540A1 (en) Anti-pla2g2d constructs and uses thereof
US20240425588A1 (en) Anti-tigit constructs and uses thereof
EP4662236A2 (en) Anti-sirp? antibodies and uses thereof
US20260078185A1 (en) Anti-vista constructs and uses thereof
WO2025259563A2 (en) Anti-cd3 constructs and uses thereof